bos161721
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT03036865)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-21INHIBITOR
IL21 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bos161721
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03371251 | Phase 1/Phase 2 (Phase 2) | Feb 7, 2018 | Boston Pharmaceuticals |
| NCT03036865 | Phase 1 | Jan 1, 2017 | Boston Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston Pharmaceuticals | For profit | 2 | 2 | 2 | 2017 |
1 organizations
Page 1 / 1